Nine Months Result 1999

AstraZeneca PLC Nine Months Results 1999 'Strong momentum maintained' Nine Months Financial Highlights Continuing Operations before Exceptional Items § Statuto Pro Forma Basis ry Basis Nine Nine Nine Constant Months Months Months Currency 1999 1999 1998 % % $m $m $m Sales: Group 13,322 13,322 11,599 + 15 + 15 Healthcare 11,148 11,148 9,276 + 20 + 21 Operating Profit: Group 3,052 3,040 2,572 + 18 + 20 Healthcare 2,792 2,780 2,226 + 25 + 26 Profit before 3,033 3,000 2,545 + 18 + 19 Tax Earnings per $1.20 $1.18 $1.00 + 18 + 19 Share All narrative in this report refers to pro forma growth rates. Tom McKillop, Chief Executive, said: "These results are further strong evidence that the merger is on track and we remain on target to achieve strong Healthcare double digit sales and profit growth for the year. " @ Healthcare sales up 20 per cent; US Healthcare sales up 29 per cent @ Healthcare operating profit up 25 per cent @ Agrochemicals sales down 7 per cent @ Group operating margin increased to 22.9 per cent ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/10/28/19991028BIT00380/bit0001.doc The full report http://www.bit.se/bitonline/1999/10/28/19991028BIT00380/bit0002.pdf The full report